Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody.
Saavedra D, Añé-Kourí AL, Gregorich EML, Mena J, Lorenzo-Luaces P, Londres HD, Martínez AH, Armada JJ, Sánchez YH, González YZ, Troche M, Medel L, Ramos M, Crombet T. Saavedra D, et al. Among authors: crombet t. Immunol Lett. 2022 Dec;251-252:1-8. doi: 10.1016/j.imlet.2022.09.005. Epub 2022 Sep 27. Immunol Lett. 2022. PMID: 36174772 Free PMC article.
Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernández E, Alvárez D, Torres O, Ramos M, Leonard I, Pérez R, Lage A. Crombet T, et al. J Clin Oncol. 2004 May 1;22(9):1646-54. doi: 10.1200/JCO.2004.03.089. J Clin Oncol. 2004. PMID: 15117987 Clinical Trial.
Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
Torres LA, Perera A, Batista JF, Hernández A, Crombet T, Ramos M, Neninger E, Pérez M, Sánchez EL, Romero S, Aguilar V, Coca MA, Iznaga-Escobar N. Torres LA, et al. Among authors: crombet t. Nucl Med Commun. 2005 Dec;26(12):1049-57. doi: 10.1097/00006231-200512000-00002. Nucl Med Commun. 2005. PMID: 16264350 Clinical Trial.
A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Rodriguez PC, Popa X, Martínez O, Mendoza S, Santiesteban E, Crespo T, Amador RM, Fleytas R, Acosta SC, Otero Y, Romero GN, de la Torre A, Cala M, Arzuaga L, Vello L, Reyes D, Futiel N, Sabates T, Catala M, Flores YI, Garcia B, Viada C, Lorenzo-Luaces P, Marrero MA, Alonso L, Parra J, Aguilera N, Pomares Y, Sierra P, Rodríguez G, Mazorra Z, Lage A, Crombet T, Neninger E. Rodriguez PC, et al. Among authors: crombet t. Clin Cancer Res. 2016 Aug 1;22(15):3782-90. doi: 10.1158/1078-0432.CCR-15-0855. Epub 2016 Feb 29. Clin Cancer Res. 2016. PMID: 26927662 Clinical Trial.
58 results